Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus
To the Editor: Localized chronic pruritus is a common condition that significantly affects health-related quality of life. A variety of diseases result in localized chronic itch, which can be broadly classified as dermatologic, neuropathic, or psychogenic in nature. For patients with chronic pruritus that is refractory to conventional therapy, the burden of disease is substantial.
Current management is directed at the underlying cause, with the majority of cases of localized chronic itch being nonhistaminergic in etiology. Treatment typically begins with nonpharmacologic therapies, adding topical glucocorticoids, topical anesthetics, coolants, topical calcineurin inhibitors, and intralesional corticosteroids in a stepwise approach.
Botulinum toxin type A (BoNT/A) is a neurotoxic protein approved by the US Food and Drug Administration for the treatment of glabellar and periorbital wrinkles, severe primary axillary hyperhidrosis, and numerous neurologic indications. 1 BoNT/A has shown potential in the medical literature as an antipruritic agent for patients with localized, chronic pruritus that is refractory to conventional therapies. BoNT/A is believed to reduce pruritic symptoms by dulling the transmission of C fiber itch signals; it may also have an effect on small fiber neuropathies by altering transmission of neural input from the peripheral nervous system. 2 We conducted a review of the current literature using the PubMed database to evaluate the use of intradermal BoNT/A in treating various types of localized chronic itch. Our search included English language articles containing the words ''botulinum'' and ''itch'' published before November 2016. We found 25 studies containing these key words dating from 1996 to 2016. Eleven articles that focused on the use of intradermal BoNT/A for the treatment of chronic refractory pruritus were included ( Table I ) . The Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow chart is shown in Fig 1. The grade of recommendation for each study was determined using the Oxford Centre for Evidence-based Medicine Levels of Evidence (Table I) .
Overall, these studies suggest the potential for BoNT/A to relieve symptoms in patients with localized chronic itch caused by brachioradial pruritus, lichen simplex, partial-to full-thickness burns, inverse psoriasis, and HaileyeHailey disease that are refractory to conventional therapy. Of note, the use of BoNT/A in treating pruritus caused by notalgia and meralgia paresthetica seems to have less consistent results, with some patients reporting significant improvements, others reporting no effect, and some reporting worsening of pruritus. With the limited number of studies, there is still insufficient evidence to make a conclusion about the effectiveness of BoNT/A in the treatment of localized chronic pruritus. Other limitations include the lack of randomized controlled trials, the small sample size in each study, the wide variety of outcome measures, and the role of placebo effect. Given these limitations, it is too early to recommend the regular use of BoNT/A in the treatment of chronic localized pruritus; however, it remains an option for the clinician in cases of recalcitrant localized pruritus. Of note, there are 3 ongoing, large-scale trials evaluating the efficacy of BoNT/A in relieving localized chronic itch caused by notalgia paresthetica, hypertrophic scars, and histamine prickeinduced itch.
Ivermectin versus permethrin in the treatment of scabies: A systematic review and meta-analysis of randomized controlled trials To the Editor: Scabies, an intensely pruritic ectoparasitic skin infestation, affects over 130 million people and hampers quality of life. 1, 2 Permethrin is considered the most effective topical treatment for scabies. 3 Ivermectin is the only oral alternative and can also be applied topically. Because randomized controlled trials comparing oral or topical ivermectin with topical permethrin have been inconclusive, we performed a meta-analysis.
On March 21, 2017, we searched PubMed, Embase, Cochrane Library, and references of included articles using the terms ''scabies'' and ''permethrin'' and ''ivermectin'' for peer-reviewed randomized controlled trials comparing oral or topical ivermectin with topical permethrin in patients with scabies. Two authors independently selected studies, extracted data, and assessed study quality using the Cochrane Risk of Bias Tool. The primary outcome was treatment failure as defined in the individual studies, although we required that the definition include persistent lesions, new lesions, or confirmation of a live mite. Secondary outcomes were persistence of itch and adverse effects. We calculated pooled risk ratios (RRs) and 95% confidence intervals (CIs) using a random effects model.
Our search identified 461 potential articles. We ultimately included 15 randomized controlled trials, which contained 2172 patients. Table I summarizes the main study characteristics. In terms of dose regimens, oral ivermectin (200 g/kg) was given as a single dose in 5 trials and repeat doses in 9 trials. Topical ivermectin (1%) was given as repeat applications in 2 trials. Topical permethrin (5%) was given as a single application in 5 trials and repeat applications in 9 trials, while topical permethrin (2.5%) was given as repeat applications in 1 trial.
Oral ivermectin was associated with a significantly increased risk of treatment failure compared with topical permethrin (RR 1.33, 95% CI 1.04-1.72, I
2 ¼ 0%, treatment failure rate: 14% [122/860] vs 10% [85/831], n ¼ 1691) (Fig 1) . Metaregression revealed no significant heterogeneity by various study characteristics: length of followup, treatment of family or close contacts, repetition of ivermectin dose, itch in definition of treatment failure, and microscopy in definition of treatment failure. Visual inspection of the funnel plot and Egger's test (P ¼ .19) revealed no
